This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.
Study Type
OBSERVATIONAL
Enrollment
10,408
Start dose and frequency at the discretion of the physician following clinical practice
Start dose and frequency at the discretion of the physician following clinical practice
Start dose and frequency at the discretion of the physician following clinical practice
Novo Nordisk Investigational Site
Moscow, Russia
Novo Nordisk Investigational Site
Kiev, Ukraine
HbA1c
Time frame: at baseline visit and during 3, 6, 9 and 12 months
Serious adverse drug reactions including major hypoglycaemic events
Time frame: during 12 months of treatment
Number of serious adverse drug reactions
Time frame: during 12 months of treatment
Number of all major (daytime and nocturnal) hypoglycaemic events
Time frame: during 12 months of treatment
Number of all minor (daytime and nocturnal) hypoglycaemic events
Time frame: During 4 weeks prior to each study visit
Weight (BMI) change
Time frame: At 6 and 12 months
Variability in fasting blood glucose values and average (mean) fasting blood glucose level
Time frame: At baseline visit and after 6 and 12 months treatment
Average post-prandial blood glucose level (2h after dinner)
Time frame: At baseline visit and after 6 and 12 months treatment
Quality of Life (QoL) as assessed by patient questionnaire
Time frame: At baseline and the end of 6 and 12 months treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.